Not Yet Recruiting OBSERVATIONAL NCT07073404

Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin (Omlyclo)

Omalizumab for the Monotherapy Treatment of Patients With Allergy to Foods of Plant Origin Due to Sensitization to Lipid Transfer Proteins (LTPs) and Profilin

Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Conditions Food Allergies

Interventions Omalizumab Injection

Updated 2 times since 2025 Last updated: Aug 6, 2025 Started: Jan 31, 2026 Primary completion: Jun 30, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Food Allergies, this trial is actively recruiting participants. The trial is conducted by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Institute of Biomedical Research in Málaga (IBIMA)

Data source: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.